Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.

Cancer letters - 1 Jan 2017

Mimoto Rei, Nihira Naoe T, Hirooka Shinichi, Takeyama Hiroshi, Yoshida Kiyotsugu

Abstract excerpt

Mammalian target of rapamycin (mTOR) inhibitor, everolimus, provides benefit for metastatic hormone receptor positive breast cancer after failure of the endocrine therapy. The present report highlights Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2 (DYRK2) as a predictive marker for everolimus sensitivity. The key node and KEGG pathway analyses revealed that mTORC1 pathway is activated in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dyrk Kinases
Share to Everolimus
Share to MCF-7 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Multiprotein Complexes

Share to TOR Serine-Threonine Kinases

Share to Tumor Burden

Share to Ubiquitination

Source

Identifiers

PMID: 27746162
DOI: 10.1016/j.canlet.2016.10.015

Genes

DYRK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.PMID 27746162Read ↗

The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic OpportunitiesSemantic proximity Read ↗

Emerging roles of DYRK2 in cancerSemantic proximity Read ↗

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

A safe haven for cancer cells: tumor plus stroma control by DYRK1BSemantic proximity Read ↗

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.Semantic proximity Read ↗

Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.Semantic proximity Read ↗

Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.Semantic proximity Read ↗

Nexus Between PI3K/AKT and Estrogen Receptor Signaling in Breast CancerSemantic proximity Read ↗

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancerSemantic proximity Read ↗

Multiple functions of DYRK2 in cancer and tissue developmentSemantic proximity Read ↗

DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesisSemantic proximity Read ↗

DYRK1A Kinase Inhibitors with Emphasis on CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.